Paul Capital

News

Year:

2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001

12/1/2006	"How to spend it" (pdf)
11/29/2006	Ortec And Paul Capital Healthcare To Restructure Existing Financing Agreement
11/29/2006	Acorda Therapeutics® to Receive Up To $10 Million From Paul Capital Healthcare
11/17/2006	Vectura Group plc ("Vectura") and Innovata plc ("Innovata") - Recommended offer for Innovata by Vectura
10/17/2006	Acorda Therapeutics Announces Expansion of Zanaflex Capsules(TM) Sales Force to 65
10/13/2006	Data on FACTIVE® Tablets Short-Course Therapy in Patients with Co- Morbidities Presented at Annual Meeting of Infectious Diseases Society of America
10/11/2006	Dyax Corp. Issued Sixth U.S. Patent in Its Phage Display Patent Portfolio
10/9/2006	First U.S. Presentation of CORTOSS® IDE Pivotal Clinical Preliminary Data To Be Presented In A Poster At The Congress Of Neurological Surgeons In Chicago
10/9/2006	Data on FACTIVE® Tablets Short- Course Therapy in Patients with Co- Morbidities Presented at Annual Meeting of Infectious Diseases Society of America
10/6/2006	Pharming Receives Orphan Product Grant From US FDA For Rhucin®
10/5/2006	Dyax Corp. Announces Funded Research Agreement with Trubion Pharmaceuticals Inc. for Discovery of Therapeutic Proteins
9/22/2006	Oscient Pharmaceuticals Receives Approvable Letter from FDA for FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
9/20/2006	AVANT Announces Latest GSK Report on Sales of Rotarix® Evidences Disagreement on Royalty Rate in Patent Countries
9/18/2006	Prism Pharmaceuticals Raises $68 Million To Advance Acute Care Portfolio
9/14/2006	Orthovita Announces First Public Podium Presentation of CORTOSS® IDE Pivotal Clinical Data in the Treatment of Vertebral Compression Fractures at the European Society of Neuroradiology Meeting in Geneva
9/13/2006	Oscient Pharmaceuticals Announces Results of FDA Advisory Committee Meeting for FACTIVE Tablets for the Treatment of Acute Bacterial Sinusitis
9/12/2006	Licensing Executives Society Announces 2006 Deals Of Distinction Awards
9/7/2006	Dyax Corp. and Serono Enter Into Library License and Funded Research Agreements for Discovery of Therapeutic Antibodies
8/24/2006	Dyax Monetizes a Portion Of Its Revenues From Phage Display Licensing And Funded Research Program For $30 MilliOn; Conference Call Scheduled At 4:30 P.M. ET Today
8/21/2006	Oscient Pharmaceuticals Completes Acquisition of Cardiovascular Therapy Antara® 130mg (Fenofibrate) Capsules; Commercialization by Oscient Sales Force to Primary Care Physicians Begins Later This Week
8/21/2006	Verus Pharmaceuticals Announces Agreement with UCB for Commercialization of Twinject® in Europe
8/17/2006	Pharming's Marketing Authorization Application for Rhucin - RHC1INH - Accepted for Review by EMEA
7/28/2006	Pharming Receives Fast Track Designation From US FDA For Recombinant Human C1 Inhibitor
6/24/2006	Oscient Pharmaceuticals Agrees to Acquire Cardiovascular Therapy Antara® 130mg (Fenofibrate) Capsules From Reliant Pharmaceuticals
6/19/2006	Bank of Ireland Group and Paul Capital Announce Private Equity Fund of Funds Joint Venture
6/14/2006	Pharming Receives Orphan Drug Designations For rhC1INH From US FDA
6/5/2006	Glenmark and Paul Capital Partners Sign Unique Royalty Deal for USD 27 Million to Build US Generic Dermatology Portfolio
4/17/2006	FDA Approves Further Changes to CORTOSS(R) IDE Pivotal Study Protocol
3/20/2006	Orthovita and Aastrom Biosciences Announce Collaboration Agreement for Orthopedic Products; Alliance to Combine Aastrom Tissue Repair Cells and Orthovita VITOSS® for Bone Tissue Regeneration
3/15/2006	AVANT Accelerates Receipt of $40 Million Milestone Payment for Rotarix®
3/7/2006	Verus Pharmaceuticals Announces Study Results Supporting the Potential Need for Two Doses of Epinephrine to Treat Anaphylaxis
2/27/2006	Rotarix: First Vaccine Against Rotavirus Available in Europe
2/3/2006	Pharming Announces Strategic Agreement Valued at US $30 Million
2/1/2006	“No cash, No problem” (pdf)
1/23/2006	Paul Royalty Fund Purchases Partial Royalty Interest In Glaxosmithkline’s Rotarix®
1/19/2006	Paul Royalty Fund Purchases Revenue Interest In Acorda’s Zanaflex Products
1/10/2006	On-X Valve Reduced Anticoagulation Clinical Trial